This page shows the publications co-authored by Evelyn Lilly and Nikolai Klebanov.
Risk of COVID-19 in Patients with Cancer Receiving Immune Checkpoint Inhibitors. Oncologist. 2021 05; 26(5):e898-e901.
Reply to: "COVID-19 vaccination in IMID patients receiving rituximab: A personalized regimen should be formulated". J Am Acad Dermatol. 2022 07; 87(1):e47-e48.
Immunosuppressive biologics did not increase the risk of COVID-19 or subsequent mortality: A retrospective matched cohort study from Massachusetts. J Am Acad Dermatol. 2022 01; 86(1):252-255.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.